Accelerating Australian vaccine and infectious disease innovation for global impact.
Biointelect Venturer is a national virtual incubator dedicated to advancing important Australian innovations for the prevention of infectious disease – from concept to commercial and investment readiness. Established through a $32.9 million Medical Research Future Fund (MRFF) grant from the Australian Government, Biointelect Venturer will support two national cohort intakes.
Biointelect Venturer will help to build local capability in translational research and commercialisation, as well as support the creation and growth of Australian biotech companies developing health technologies across the infectious disease sector.
Ultimately, our ambition is to strengthen Australia’s position as a global infectious disease innovation hub.
Biointelect Venturer – Round 1:
On 31 August 2026, Biointelect Venturer announced the investment of $10.48 million into six Australian infectious disease innovations being developed by companies to accelerate commercial potential. The six companies in will be part of the Biointelect Venturer incubator program for up to two years.
Round 1 Investment Awardees:
AdaptiVax Pty Ltd (Victoria) – $1.0 million: developing an adaptable virus-like particle (VLP) vaccine platform technology designed to enable the rapid development of vaccines against multiple respiratory viruses, initially targeting RSV, human metapneumovirus and parainfluenza virus.
Ebivanta Therapeutics Pty Ltd (Queensland) – $1.5 million: developing an mRNA vaccine against Epstein-Barr virus (EBV), with the potential to help prevent EBV infection and reduce the long-term risk of serious diseases associated with the virus.
ENA Respiratory Pty Ltd (Victoria) – $2.98 million: developing Nasal Defence Enhancer (INNA-051), a nasal spray treatment designed to boost the human airways’ natural antiviral defences and provide an additional layer of protection against respiratory illness alongside vaccination
Proboxis Biotechnology Pty Ltd (Queensland) – $1.5 million: developing a vaccine production platform for mosquito-borne viruses, beginning with Japanese encephalitis, with the potential to support the development of vaccines against other mosquito-borne viruses.
Saccharide Therapeutics Pty Ltd (Victoria) – $1.5 million: developing ST101, a malaria vaccine targeting a specific structure consistent across all species and life cycle stages, with the potential for broader protection against different malaria parasites and at various stages of infection.
SAMMVax Pty Ltd (Queensland) – $2.0 million: developing TriVax, a trivalent vaccine designed to provide broad protection against Strep A, a bacterial infection that can lead to serious complications including sepsis, rheumatic fever and rheumatic heart disease.
Cohort 1 Announcement Video
